Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Biologics
Explore the latest data on biologic drug approvals. Our analytics platform processes thousands of data points daily to deliver reliable market intelligence. Market conditions change rapidly, and staying informed is crucial for making sound decisions. This page aggregates the most relevant data points and presents them in an easily digestible format.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug | Type | Target | Company | Year |
|---|---|---|---|---|
| Pembrolizumab ext | mAb | PD-1 | ImmunoLabs | 2026 |
| Trastuzumab-next | ADC | HER2 | OncoPharm | 2026 |
| AAV-CFTR | Gene therapy | Cystic fibrosis | GeneTech | 2025 |
| CAR-T v3 | Cell therapy | ALL | CellThera | 2025 |
| Bispecific-001 | BiTE | DLBCL | BioSpec | 2025 |
The complete dataset for this page is available in machine-readable JSON for developers and data pipelines — direct API endpoint, no auth, no page rendering required: https://fdanews.online/api/dataset/export?token=03c47695ffa0b50e819f8aa8545276bcFull Data Export
